Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C Pyruvate MRI in Primary CNS Lymphoma
NCT04656431Phase 1Recruiting
- Start
- Jun 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Hyperpolarized Pyruvate (13C) Injection + Gadolinium in primary central nervous system lymphoma (PCNSL) (2 cohorts). Primary endpoints: Proportion of participants with treatment-emergent Adverse Events at 1 day, Number of participants with abnormal changes in vital signs at 1 day and 6 more. Started Jun 2021; status: recruiting.
02
Drugs
Hyperpolarized Pyruvate (13C) Injection + Gadolinium
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04656431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656431.